PortViewPortView
Tourmaline Bio logo

Tourmaline Bio (TRML) Stock Analysis

NASDAQHealthcareBiotechnology

$47.98+0.00%
1-year price historyRange $12.10 – $48.16
52-week range$47.98
$11.56$48.27

What Tourmaline Bio does

Tourmaline Bio, Inc. is a clinical-stage biotechnology firm committed to advancing therapies for individuals suffering from debilitating immune disorders. The company's development pipeline focuses on conditions such as Atherosclerotic Cardiovascular Disease (ASCVD) and Thyroid Eye Disease (TED). Established in 2021, this enterprise is headquartered in New York, New York.

Key metrics

Market cap
$1.23B
P/E (TTM)
-13.95
EPS (TTM)
$-3.44
Beta
1.58
Dividend yield
0.00%
Revenue / share
$0.00
50-day avg
$40.68
200-day avg
$22.74
52-week high
$48.27
52-week low
$11.56
CEO
Sandeep C. Kulkarni

ETFs linked to TRML

Broad-market and Healthcare sector ETFs an investor holding Tourmaline Bio is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how TRML fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze TRML in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Tourmaline Bio?
Tourmaline Bio trades under the ticker TRML on NASDAQ.
Which exchange is TRML listed on?
TRML is listed on NASDAQ.
What sector does Tourmaline Bio operate in?
Tourmaline Bio is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze TRML in a portfolio?
PortView shows TRML's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.